Distinct Relations Among Plasma Concentrations Required for Different Pharmacological Effects in Oxycodone, Morphine, and Fentanyl

REFERENCES

• Twycross RG, Lack SA. Control of Alimentary Symptoms in Far Advanced Cancer. London: Churchill Livingstone, London; 1986:166–207.
   Google Scholar
• Bruera E, Watanabe S. Psychostimulants as adjuvant analgesics. J Pain Symptom Manage. 1994;9:412–415.
   PubMed Web of Science ®Google Scholar
• O'Mahony S, Coyle N, Payne R. Current management of opioid-related side effects. Oncology (Williston Park). 2001;15:61–73, 77–78, 80–82.
   Google Scholar
• McNicol E, Horowicz-Mehler N, Fisk RA, Bennett K, Gialeli-Goudas M, Chew PW, Lau J, Carr D, American Pain Society. Management of opioid side effects in cancer-related and chronic noncancer pain: a systematic review. J Pain. 2003;4:231–256.
   PubMed Web of Science ®Google Scholar
• Hartung DM, Middleton L, Haxby DG, Koder M, Ketchum KL, Chou R. Rates of adverse events of long-acting opioids in a state Medicaid program. Ann Pharmacother. 2007;41:921–928.
   Google Scholar
• Ordonez Gallego A, Gonzalez Baron M, Espinosa Arranz E. Oxycodone: a pharmacological and clinical review. Clin Transl Oncol. 2007;9:298–307.
   Google Scholar
• Narabayashi M, Saijo Y, Takenoshita S, Chida M, Shimoyama N, Miura T, Tani K, Nishimura K, Onozawa Y, Hosokawa T, Kamoto T, Tsushima T, Advisory Committee for Oxycodone Study. Opioid rotation from oral morphine to oral oxycodone in cancer patients with intolerable adverse effects: an open-label trial. Jpn J Clin Oncol. 2008;38:296–304.
   PubMed Web of Science ®Google Scholar
• Megens AA, Artois K, Vermeire J, Meert T, Awouters FH. Comparison of the analgesic and intestinal effects of fentanyl and morphine in rats. J Pain Symptom Manage. 1998;15:253–257.
   PubMed Web of Science ®Google Scholar
• Lotsch J. Pharmacokinetic-pharmacodynamic modeling of opioids. J Pain Symptom Manage. 2005;29:S90–S103.
   PubMed Web of Science ®Google Scholar
• Mucci-LoRusso P, Berman BS, Silberstein PT, Citron ML, Bressler L, Weinstein SM, Kaiko RF, Buckley BJ, Reder RF. Controlled-release oxycodone compared with controlled-release morphine in the treatment of cancer pain: a randomized, double-blind, parallel-group study. Eur J Pain. 1998;2:239–249.
   PubMed Web of Science ®Google Scholar
• Staahl C, Upton R, Foster DJ, Christrup LL, Kristensen K, Hansen SH, Arendt-Nielsen L, Drewes AM. Pharmacokinetic-pharmacodynamic modeling of morphine and oxycodone concentrations and analgesic effect in a multimodal experimental pain model. J Clin Pharmacol. 2008;48:619–631.
   PubMed Web of Science ®Google Scholar
• Narita M, Imai S, Itou Y, Yajima Y, Suzuki T. Possible involvement of mu1-opioid receptors in the fentanyl- or morphine-induced anti-nociceptive effect at supraspinal and spinal sites. Life Sci. 2002;70:2341–2354.
   PubMed Web of Science ®Google Scholar
• Narita M, Nakamura A, Ozaki M, Imai S, Miyoshi K, Suzuki M, Suzuki T. Comparative pharmacological Profiles of morphine and oxycodone under a neuropathic pain-like state in mice: evidence for less sensitivity to morphine. Neuropsychopharmacology. 2008;33:1097–1112.
   PubMed Web of Science ®Google Scholar
• Lemberg KK, Kontinen VK, Siiskonen AO, Viljakka KM, Yli-Kauhaluoma JT, Korpi ER, Kalso EA. Anti-nociceptive effect by spinal and systemic oxycodone: why does the route make a difference? Anesthesiology. 2006;105:801–812.
   PubMed Web of Science ®Google Scholar
• Lemberg K, Kontunen VK, Viljakka K, Kylanlahti I, Yli-Kauhaluoma J, Kalso E. Morphine, oxycodone, methadone and its enantiomers in different models of nociception in the rat. Anesth Analg. 2006;102:1768–1774.
   PubMed Web of Science ®Google Scholar
• Schug SA, Zech D, Grond S. Adverse effects of systemic opioid analgesics. Drug Safety. 1992;7:200–213.
   PubMed Web of Science ®Google Scholar
• Lawlor PG and Bruera E. Side-effects of opioids in chronic pain treatment. Curr OpinAnaesthesiol. 1998;11:539–545.
   Google Scholar
• Holzer P. Treatment of opioid-induced gut dysfunction. Expert Opin Invest Drugs 2007;16:181–194.
   PubMed Web of Science ®Google Scholar
• Mansour A, Fox CA, Aki H, Watson SJ. Opioid-receptor mRNA expression in the rat CNS: anatomical and functional implications. Trends Neurosci. 1995;18:22–29.
   PubMed Web of Science ®Google Scholar
• Jordan BA, Devi LA. G-protein-coupled receptor heterodimerazation modulates receptor function. Nature. 1999;17:697–700.
   Google Scholar
• Gomes I, Jordan BA, Gupata A, Trapaidze N, Nagy V, Devi LA. Heterodimerization of mu and delta opioid receptors: a role in opiate synergy. J Neurosci. 2000;15:RC110.
   Google Scholar
• Galandrin S, Oligny-Longpre G, Bouvier M. The evasive nature of drug efficacy: implications for drug discovery. Trends Pharmacol Sci. 2007;28:423–430.
   PubMed Web of Science ®Google Scholar
• Pan YX, Xu J, Xu M, Rossi GC, Matulonis JE, Pasternak GW. Involvement of exon 11-associated variants of the mu opioid receptor MOR-1 in heroin, but not morphine, actions. Proc Natl Acad Sci U S A. 2009;24:4917–4922.
   Google Scholar
• McPherson J, Rivero G, Baptist M, Llorente J, Al-Sabah S, Krasel C, Dewey WL, Bailey CP, Rosethorne EM, Charlton SJ, Henderson G, Kelly E. μ-Opoioid receptors: correlation of agonist efficacy for signaling with ability to activate internalization. Mol Pharmacol. 2010;78:756–766.
   PubMed Web of Science ®Google Scholar